Susquehanna International Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-59,168
Closed -$286K 11421
2020
Q1
$286K Buy
59,168
+34,245
+137% +$222K ﹤0.01% 8078
2019
Q4
$265K Sell
24,923
-33,869
-58% -$336K ﹤0.01% 8252
2019
Q3
$612K Buy
58,792
+14,051
+31% +$184K ﹤0.01% 6815
2019
Q2
$685K Buy
+44,741
New +$647K ﹤0.01% 6566
2019
Q1
Sell
-195,237
Closed -$2.21M 10324
2018
Q4
$1.85M Buy
195,237
+125,186
+179% +$1.62M ﹤0.01% 3633
2018
Q3
$1.16M Buy
70,051
+25,286
+56% +$405K ﹤0.01% 4928
2018
Q2
$718K Buy
+44,765
New +$799K ﹤0.01% 6083
2018
Q1
Sell
-36,579
Closed -$570K 10598
2017
Q4
$571K Buy
36,579
+10,665
+41% +$143K ﹤0.01% 6392
2017
Q3
$288K Buy
+25,914
New +$244K ﹤0.01% 7477
2017
Q2
Sell
-75,746
Closed -$632K 10138
2017
Q1
$648K Buy
75,746
+6,824
+10% +$62.2K ﹤0.01% 6003
2016
Q4
$737K Buy
+68,922
New +$834K ﹤0.01% 6166
2016
Q2
Sell
-44,988
Closed -$210K 9660
2016
Q1
$210K Buy
44,988
+33,685
+298% +$165K ﹤0.01% 7887
2015
Q4
$71K Sell
11,303
-21,202
-65% -$172K ﹤0.01% 9013
2015
Q3
$287K Buy
32,505
+19,072
+142% +$200K ﹤0.01% 8114
2015
Q2
$158K Buy
13,433
+1,683
+14% +$23.4K ﹤0.01% 9466
2015
Q1
$170K Sell
11,750
-578
-5% -$8.85K ﹤0.01% 8746
2014
Q4
$210K Sell
12,328
-6,815
-36% -$98.3K ﹤0.01% 8748
2014
Q3
$239K Buy
+19,143
New +$236K ﹤0.01% 8375
2014
Q1
Sell
-10,568
Closed -$207K 9635
2013
Q4
$207K Buy
+10,568
New +$282K ﹤0.01% 8215

Susquehanna International Group's STML Position: Q2 2020 in Review

Susquehanna International Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 59,168 shares — an estimated $286K sold.

Susquehanna International Group first reported a position in STML in Q4 2013 and held it in 19 quarters. The position peaked at $1.85M in Q4 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Susquehanna International Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Susquehanna International Group sold 59,168 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $286K.
  • Susquehanna International Group first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 19 quarters.
  • Susquehanna International Group's Stemline Therapeutics, Inc. position peaked at $1.85M in Q4 2018.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Susquehanna International Group's 13F filing for Q2 2020, filed 14 Aug 2020.